Welcome to our dedicated page for Nuwellis news (Ticker: $NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuwellis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuwellis's position in the market.
Rhea-AI Summary
Nuwellis, Inc. (NUWE) to showcase its Aquadex SmartFlow system at THT 2024 conference, featuring presentations by key experts on new developments in aquapheresis and AI-assisted identification of super responders for heart failure management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
-
Rhea-AI Summary
Nuwellis, Inc. announces promising findings for Aquadex SmartFlow® system in treating fluid overload in end-stage liver disease patients. The new data demonstrates the potential value of aquapheresis therapy in removing excess fluid for patients who don't respond to diuretics, offering a new market opportunity for the company. The study shows positive results in treating patients with end-stage liver disease, including improved mobility, reduced frailty, and the potential to enhance their ability to receive a life-saving liver transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
News
Rhea-AI Summary
Nuwellis, Inc. (Nasdaq: NUWE) has received FDA clearance for its specialty peripheral dual lumen extended length catheter (dELC), providing an alternative peripheral access for ultrafiltration therapy across a broad range of patient physiologies. The new 12 cm dELC offers the same features as the longer 16 cm option but eliminates the need for trimming when a shorter catheter is needed. The Aquadex system is proven to remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. It is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
Rhea-AI Summary
Nuwellis, Inc. (NUWE) announces new real-world data demonstrating the effectiveness of Aquadex® ultrafiltration therapy with continuous hematocrit monitoring for pediatric patients with fluid overload. The data, featured in Pediatric Nephrology, show successful treatment of small patients without complications, validating Aquadex as an effective treatment option for fluid overload.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nuwellis, Inc. (NUWE) Approves Equity Awards Under 2021 Inducement Plan for New Hires. The company's independent directors approved equity awards as material inducements to five individuals entering into employment with the company. The options to purchase a total of 1,943 shares of the company's common stock were granted at an exercise price of $0.60 per share, with a ten-year term and vesting over a period of four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Nuwellis, Inc. reported a 17% revenue growth for the third quarter of 2023, driven by a 26% increase in circuit sales. The company also achieved a 26% increase in therapy utilization and continued revenue growth across all customer categories. Despite a decrease in gross margin and a net loss of $3.4 million, Nuwellis closed a public offering with gross proceeds of $2.25 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
Rhea-AI Summary
Nuwellis, Inc. has appointed Dave McDonald and Dr. Archelle Georgiou, MD, to its board of directors. McDonald has extensive experience in finance and strategy, while Dr. Georgiou brings expertise in healthcare policy and patient education. The company aims to drive market penetration of its Aquadex® ultrafiltration therapy for patients with fluid overload.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
-
Rhea-AI Summary
Nuwellis, Inc. announces that its strategic partner, SeaStar Medical Holding Corporation, has received an Approvable Letter from the FDA for its pediatric Selective Cytopheretic Device (SCD-PED). The SCD-PED will provide a new therapy option for children with acute kidney injury and sepsis. The Approvable Letter indicates that SeaStar Medical's HDE application meets the requirements for an Approval Order, with minor administrative steps remaining. Clinical data showed a 77% reduction in mortality rate and no dialysis dependency at Day 601,2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
-
Rhea-AI Summary
Nuwellis, Inc. to release Q3 2023 financial results on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
Rhea-AI Summary
Nuwellis, Inc. has closed its public offering of 150,000 units, consisting of Series J Convertible Redeemable Preferred Stock and warrants. The purchase price for one unit was $15. The Series J Convertible Preferred Stock has a term of three years and is convertible at the option of the holder. Dividends on the Series J Convertible Preferred Stock will be paid in-kind in additional shares. The gross proceeds from the offering were approximately $2.25 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
Nuwellis, Inc.
Nasdaq:NUWE
NUWE Rankings
NUWE Stock Data
1.22M
6.79M
0.06%
3.14%
12.08%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
EDEN PRAIRIE
About NUWE
chf solutions is an early stage company focused on commercializing the aquadex flexflow system. our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. at chf solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community. if you are looking for a career where you can make difference we would like to hear from you. we are looking for highly skilled, highly motivated people who want to be part of a growing company where everything you do will matter. chf solutions is an equal opportunity/affirmative action employer committed to cultural diversity in the workplace.